Tag Archives: Generic Medicine (TRBC level 5)

Britain is extending its COVID-19 vaccine supply deal with India’s Wockhardt | Instant News


A bottle labeled “COVID-19 Coronavirus Vaccine” and a sryinge is seen in front of the British flag emblazoned in this illustration taken, 9 February 2021. REUTERS / Dado Ruvic / Illustration

BENGALURU (Reuters) – Britain has extended a deal with Wockhardt Ltd for the supply of the COVID-19 vaccine for six months, the Indian drugmaker said on Wednesday.

The agreement is now being extended to August 2022, and Wockhardt will continue to make the vaccine at his unit at Wrexham in Wales, the company said. It doesn’t reveal any financial details of the deal.

Reporting by Sachin Ravikumar in Bengaluru; Edited by Shounak Dasgupta

.



image source

Analysis: “Russian roulette” in Europe due to a shortage of syringes is preventing the COVID-19 firing | Instant News


PARIS / BERLIN (Reuters) – Laurent Fignon, a geriatric doctor in southern France, had to improvise while administering Pfizer and BioNTech’s Covid-19 vaccine shots to orphanage residents and health workers because of the proper supply of syringes. and a short syringe.

Getting six full doses from a Pfizer / BioNTech syringe – as permitted this month by European Union health regulators – requires a needle thin enough to minimize waste and long enough to deliver the injection, as needed, to the recipient’s shoulder muscle.

Fignon hospital in the Mediterranean resort of Cannes was sent syringes from French public health authorities that were too short, he said, forcing him to hunt for supplies locally. Other nearby hospitals got proper syringes and were generous enough to share several.

“For us, it is like Russian roulette,” Fignon told Reuters. “You don’t know what you will get.”

Similar shortcomings emerged elsewhere in Europe, complicating the stuttering beginnings of vaccination efforts that have been exacerbated by warnings from Pfizer and AstraZeneca, its Anglo-Swedish partner, that they will not be able to meet vaccine supply commitments any time soon.

Pfizer now predicts it will produce 2 billion doses this year, but this assumes that it will be possible to extract the full six from each bottle. It fills on a dose basis, meaning the cost of the bottle has gone up by 20%.

The European Commission is urging Pfizer and German partner BioNTech to provide more low dead space needles to extract extra doses.

BioNTech says it has purchased 50 million marketable needles to countries around the world, and is working to buy more. That compares with the EU order for up to 600 million doses of its vaccine.

Industry executives say that, while the yield of syringes is sufficient to meet current demand, chaotic ordering means they often don’t reach where they need it most. Work is underway to assess future demand and find ways to meet it, they said.

FILE PHOTOS: A vial and sryinge seen in front of the Pfizer and Biontech logos shown in the illustration taken on January 11, 2021. REUTERS / Dado Ruvic / Illustration / File Photo

COORDINATED CALLS

In Germany, vaccine distribution is handled by the central government but 16 federal states are responsible for obtaining the syringes needed to inject them – with mixed results.

Some, like Baden-Wuerttemberg and Thuringia, have had the luck of ordering the right needles and syringes early on. But others, including Bavaria, Saarland and Lower Saxony, did not and had to carry out follow-up orders, officials said.

Saxony, on the Czech border, also has to shop as scarce supplies push prices up, said Lars Werthmann, regional head of vaccine logistics at the German Red Cross.

“We can’t miss a single dose at this point. And we cannot justify failure for a 5 cent syringe, “Werthmann told Reuters.

Europe’s leading injection equipment manufacturer, a private German company called B.Braun, said it was facing increased demand for syringes and other products needed for vaccination.

“With our competitors, we are currently able to meet all the demands regarding the products required for vaccination,” said spokeswoman Christine Bossek. “We are working on solutions in parallel to ensure that this will also happen in the future.”

The German medical technology industry association, BVMed, said there were no production barriers and the supply of syringes and syringes was sufficient. But chaotic orders make distribution difficult, he added, calling for better coordination.

SHOOTING DEVICES

Switzerland has ordered so-called “firing equipment” to deliver five doses per bottle. With six now permitted, it is in talks with Pfizer to supply the equipment needed to withdraw those doses, the Federal Office of Public Health said.

Officials in the UK, which have started vaccination efforts earlier, say the health team is equipped with the right injection equipment.

Back in Cannes, Fignon says he and his colleagues have managed to extract six doses from a Pfizer bottle but this will not last unless doctors get the equipment they need.

“Some countries have the right equipment from the start; we are not here in France, “he said. The French health ministry has acknowledged that extracting the sixth dose is challenging and requires specialized equipment. It said it was in the process of making sure the right syringe reached the doctor.

In addition to BioNTech’s pledge to supply syringes at a cost, Pfizer said it was in discussions with the European Commission and EU governments about their vaccination plans, including “supporting governments in securing a low supply of dead space syringes if they need them”.

Additional reporting by John Miller in Zurich, Francesco Guarascio in Brussels, Alistair Smout in London and Ludwig Burger in Frankfurt; Written by Douglas Busvine; Edited by Nick Macfie

.



image source

The Brazilian company plans to start making a Russian vaccine next week | Instant News


FILE PHOTO: A medical worker fills a syringe with the Sputnik V (Gam-COVID-Vac) vaccine as she prepares to vaccinate service members of the Russian Army at a clinic in the city of Rostov-On-Don, Russia December 22, 2020. REUTERS / Sergey Pivovarov / Photo files

BRASILIA (Reuters) – Brazilian pharmaceutical company Uniao Quimica plans to start producing Russia’s Sputnik V vaccine for COVID-19 in Brazil as early as next week and make up to 8 million doses a month, international business director Rogerio Rosso said on Friday.

Private companies, with vaccine facilities in Brasilia, are preparing to seek emergency use permission from health regulator Anvisa for a vaccine developed in Moscow.

Uniao Quimica last week sought approval to carry out a Phase III clinical trial in Brazil, which is required for licensing the vaccine in the country.

“We are waiting for Anvisa’s authorization to start clinical studies here,” Rosso told Reuters.

Uniao Quimica is working with the Russian Direct Investment Fund (RDIF), which markets Sputnik V around the world, to get an emergency use authorization that will allow the vaccine to be included in Brazil’s state vaccination plan that will start at the end of the month.

“Next week we will start producing vaccines. Our plan is very quickly to reach 8 million doses per month, ”said Rosso.

The Brazilian state governments of Bahia, Parana and PIaui will partner with the company in conducting clinical trials, he said.

RDIF said it wanted to produce a two-shot vaccine in Brazil for export to other countries in Latin America.

Argentina began vaccinating its citizens last week with an imported dose of Sputnik V, the only vaccine so far administered in the country.

Reporting by Anthony Boadle; Edited by Leslie Adler and Jonathan Oatis

.



image source

The Brazilian company plans to start making a Russian vaccine next week | Instant News


FILE PHOTO: A medical worker fills a syringe with the Sputnik V (Gam-COVID-Vac) vaccine as she prepares to vaccinate service members of the Russian Army at a clinic in the city of Rostov-On-Don, Russia December 22, 2020. REUTERS / Sergey Pivovarov / Photo files

BRASILIA (Reuters) – Brazilian pharmaceutical company Uniao Quimica plans to start producing Russia’s Sputnik V vaccine for COVID-19 in Brazil as early as next week and make up to 8 million doses a month, international business director Rogerio Rosso said on Friday.

Private companies, with vaccine facilities in Brasilia, are preparing to seek emergency use permission from health regulator Anvisa for a vaccine developed in Moscow.

Uniao Quimica last week sought approval to carry out a Phase III clinical trial in Brazil, which is required for licensing the vaccine in the country.

“We are waiting for Anvisa’s authorization to start clinical studies here,” Rosso told Reuters.

Uniao Quimica is working with the Russian Direct Investment Fund (RDIF), which markets Sputnik V around the world, to get an emergency use authorization that will allow the vaccine to be included in Brazil’s state vaccination plan that will start at the end of the month.

“Next week we will start producing vaccines. Our plan is very quickly to reach 8 million doses per month, ”said Rosso.

The Brazilian state governments of Bahia, Parana and PIaui will partner with the company in conducting clinical trials, he said.

RDIF said it wanted to produce a two-shot vaccine in Brazil for export to other countries in Latin America.

Argentina began vaccinating its citizens last week with an imported dose of Sputnik V, the only vaccine so far administered in the country.

Reporting by Anthony Boadle; Edited by Leslie Adler and Jonathan Oatis

.



image source

Modi from India visited a major vaccine facility as COVID-19 cases escalated | Instant News


NEW DELHI (Reuters) – Indian Prime Minister Narendra Modi visited the country’s three leading vaccine development and production sites on Saturday as coronavirus cases continue to rise.

India has recorded 9.35 million COVID-19 infections, second only to the United States. It reported 41,322 new cases and 485 deaths as of Saturday.

The western state of Maharashtra – home to India’s financial hub Mumbai – has been hard hit by the virus. The tally is 1.68 million cases higher than for countries such as Spain, Italy and the UK.

Modi undertook a three-city whirlwind tour and visited the Zydus Cadila facility in the western city of Ahmedabad, the Bharat Biotech facility in the southern hub of Hyderabad and the sprawling campus at the Serum Institute of India in the western city of Pune.

After the visit, Modi said India’s role in developing the vaccine was a global good and he was pleased with the rapid progress being made.

“It is India’s duty to assist other countries, including countries in our neighborhood, in the collective fight against the virus,” Modi said in a statement.

The company is testing self-developed vaccine options, as well as working on trials of vaccines being developed overseas.

The Serum Institute, the world’s largest vaccine producer, has partnered with global players including AstraZeneca and Novavax Inc to run domestic trials on their vaccine candidates and produce vaccines, if they get approval.

Zydus Cadila is developing the original DNA-based vaccine, ZyCov-D, while privately owned Bharat Biotech is working on a vaccine candidate called COVAXIN in collaboration with the state-run Indian Medical Research Council.

India hopes to complete its final test on COVAXIN in a month or two, said health minister Harsh Vardhan earlier this month.

Reporting by Nidhi Verma; Edited by Euan Rocha and Christina Fincher

.



image source